Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in...
– Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four...
DOVER, Del., March 25, 2025 /PRNewswire/ -- The Mom's Choice Awards® has named Elora*, from leading technology startup LittleOne.Care™, as among...
Initial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) --...
Initial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) --...
Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in CanadaLONDON...
sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved,...
Mara Castro will lead engineering, product, marketing, and customer experience operations as Twentyeight Health expands essential sexual and reproductive telehealth...
New digital health partners in specialty care, digestive health, fertility, and family building available for Teladoc Health care team referral...
NEW YORK, March 10, 2025 /PRNewswire/ -- Sidekick Health, a leading digital health company, today announced the launch of a...
Arkansas moms get access to customized content and information on essential state resources for a healthier pregnancy CAMBRIDGE, Mass. &...
Arkansas moms get access to customized content and information on essential state resources for a healthier pregnancy CAMBRIDGE, Mass. &...
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also...
Centered on personalizing the patient experience for expecting and new parents, Pacify is revolutionizing virtual care to drive better outcomes...
VIVUS reaffirms commitment to combatting global obesity crisis on World Obesity Day 2025 with VIVUS For Life CAMPBELL, Calif., March...
ROXYBOND, formulated with patented, first-of-its-kind abuse-deterrent technology SentryBond™, is designed to provide multiple levels of protection PRINCETON, N.J., March 3, 2025...
New website launched in honor of Rare Disease Day, Feb. 28, 2025 Awareness campaign includes educational resources and testing information...
Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE® (pegcetacoplan injection) full year 2024 net product...
The solution features clinically proven digital diagnostics and therapy, delivering up to 20% immediate PPD symptom relief and 30-40% improvement...
Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million, representing a 51% increase over the same period in...